Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109477 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25366224 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL15369081 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL13983301 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25365258 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25366902 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25365949 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24268977 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL10177866 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL11498283 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114034787-B | Method for measuring sensory related amide compounds in main stream smoke of cigarettes | 中国烟草总公司郑州烟草研究院 | 2024-05-03 | — | — | CN | claimed |
| CN-114034790-B | Method for determining sensory related amide compounds in tobacco and tobacco products | 中国烟草总公司郑州烟草研究院 | 2024-03-08 | — | — | CN | claimed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-114034787-B | Method for measuring sensory related amide compounds in main stream smoke of cigarettes | 中国烟草总公司郑州烟草研究院 | 2024-05-03 | — | — | CN | disclosed |
| CN-114034790-B | Method for determining sensory related amide compounds in tobacco and tobacco products | 中国烟草总公司郑州烟草研究院 | 2024-03-08 | — | — | CN | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-114034787-A | Method for determining sensory related amide compounds in cigarette mainstream smoke | 中国烟草总公司郑州烟草研究院 | 2022-02-11 | — | — | CN | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9079929-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140274960-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| EP-0190685-B1 | HETEROCYCLIC AMIDES | G.D. Searle & Co. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4981853-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS | G. D. SEARLE & CO. (US) | 1991-01-01 | — | — | US | disclosed |
| US-4959364-A | Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides | G. D. SEARLE & CO. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0190685-A2 | Heterocyclic amides | G.D. Searle & Co. (US) | 1986-08-13 | — | — | EP | disclosed |
| US-4209445-A | FROM PIPERONAL AND A CROTONIC AMIDE IN PRESENCE OF QUATERNARY AMMONIUM OR PHOSPHONIUM HYDROXIDE OR CROWN ETHER METAL COMPLEX | HAARMAN & REIMER GMBH (DE) | 1980-06-24 | — | — | US | disclosed |
| US-4209446-A | FROM PIPERONAL AND A CROTONIC AMIDE IN PRESENCE OF ALKALI METAL HYDROXIDE AND DIPOLAR APROTIC DILUENT | HAARMAN & REIMER GMBH (DE) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | ALDH1A1 4610/4885MAPT 1583/4885HPGD 3547/4885 |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALDH1A1 4505/4885MAPT 2246/4885HPGD 3518/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | ALDH1A1 4610/4885MAPT 1583/4885HPGD 3547/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | ALDH1A1 4610/4885MAPT 1583/4885HPGD 3547/4885 |
| US-20140274960-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | ALDH1A1 3202/4885MAPT 4429/4885HPGD 813/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | ALDH1A1 4505/4885MAPT 2246/4885HPGD 3518/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | ALDH1A1 4610/4885MAPT 1583/4885HPGD 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.